Clinical Profile of RSV Breakthrough Infections After Nirsevimab Introduction
Viruses · 2026
DOI: 10.3390/v18101107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2026. Verfasst von Anna Chiara Vittucci und 11 weiteren Autor:innen. Beteiligte Einrichtung: General Pediatric and Infectious Disease Unit, Pediatric Emergency Medicine, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antiviral Agents, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Italian Ministry of Health.
Abstract (Originalsprache)
The introduction of universal prophylaxis with nirsevimab for all children in their first epidemic season has substantially reduced the burden of respiratory syncytial virus (RSV). However, a small number of breakthrough infections continue to occur despite immunization, mostly in previously healthy infants, and these cases remain incompletely characterized. We conducted a retrospective study across three epidemic seasons at a third-level hospital, including 536 RSV-positive children under 12 months of age hospitalised for bronchiolitis. Immunised infants with breakthrough infection showed a higher prevalence of prematurity and comorbidities than unimmunised infants, and were more frequently represented in the 9–12-month age group, with a median of 291 days since nirsevimab administration. Immunised infants had significantly lower odds of requiring supplemental oxygen (aOR 0.33, 95% CI 0.19–0.57, p < 0.001). However, once oxygen therapy was required, immunisation status did not independently predict the need for advanced ventilatory support. Severe breakthrough cases requiring invasive mechanical ventilation occurred even among infants without traditional risk factors. These findings confirm the substantial real-world impact of universal nirsevimab prophylaxis while underscoring the need for continued clinical vigilance and further research into the mechanisms underlying breakthrough disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Pediatric and Infectious Disease Unit, Pediatric Emergency Medicine, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
- Neonatal Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
- Microbiology and Diagnostic Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
- Systems Medicine Departments, Tor Vergata University of Rome, 00133 Rome, Italy.
ORCID-Profile: Anna Chiara Vittucci, Alessandra Salvatori, Domenico Umberto De Rose, Mara Pisani, Andrea Dotta, Alberto Villani
Förderung
- Ministry of Health
- Italian Ministry of Health
Zitieren
APA
Vittucci, A. C., Antilici, L., Salvatori, A., De Rose, D. U., Scutari, R., Di Maio, V. C., Rotondi Aufiero, L., Pisani, M., Musolino, A. M., Dotta, A., Perno, C. F., & Villani, A. (2026). Clinical Profile of RSV Breakthrough Infections After Nirsevimab Introduction. Viruses. https://doi.org/10.3390/v18101107
Vancouver
Vittucci AC, Antilici L, Salvatori A, De Rose DU, Scutari R, Di Maio VC, et al. Clinical Profile of RSV Breakthrough Infections After Nirsevimab Introduction. Viruses. 2026. doi:10.3390/v18101107
BibTeX
@article{Vittucci2026,
author = {Vittucci, Anna Chiara and Antilici, Livia and Salvatori, Alessandra and De Rose, Domenico Umberto and Scutari, Rossana and Di Maio, Velia Chiara and Rotondi Aufiero, Lelia and Pisani, Mara and Musolino, Anna Maria and Dotta, Andrea and Perno, Carlo Federico and Villani, Alberto},
title = {Clinical Profile of RSV Breakthrough Infections After Nirsevimab Introduction},
journal = {Viruses},
year = {2026},
doi = {10.3390/v18101107}
}
EUVIMED